NASDAQ:AFMD - Affimed N.V.
$3.15
 $0.02
+0.64%
4:00PM EDT
2019-07-15
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  AFMD     avg for
industry  
  avg for
sector  
42 stocks weight:  -1000. 00   114. 77   204. 78  
42 stocks rank:  4. 47 K 1. 44 K 810. 33  
# analyst opinions:  6. 00   13. 59   13. 86  
mean recommendation:  1. 50   2. 12   2. 04  

quick ratio:  3. 14   5. 48   1. 89  
current ratio:  3. 17   5. 85   2. 40  

target price low:  3. 22   82. 72   115. 11  
target price avg:  6. 06   104. 42   138. 02  
target price high:  7. 25   130. 64   159. 47  
1-yr high:  6. 15   110. 27   142. 72  
last close:  3. 13   85. 12   126. 54  
50-day avg:  3. 13   86. 06   122. 35  
200-day avg:  3. 55   88. 76   121. 75  
1-yr low:  1. 45   69. 26   100. 63  
volume:  742. 47 K 3. 51 M 5. 53 M
50-day avg volume:  979. 82 K 3. 21 M 4. 22 M
200-day avg volume:  893. 25 K 3. 04 M 4. 75 M

1-day return:  5. 03 % -0. 30 % -1. 01 %
this week return:  7. 56 % -2. 16 % -1. 35 %
12-wk return:  -6. 57 % 3. 34 % 8. 69 %
52-wk return:  57. 78 % -1. 76 % 12. 22 %

enterprise value (EV):  177. 30 M 46. 50 B 123. 99 B
market cap:  196. 79 M 40. 77 B 109. 11 B
debt/equity:  10. 96   57. 36   120. 25  

shares outstanding:  0. 00   551. 08 M 1. 24 B
shares:  50. 33 M 559. 41 M 1. 22 B
shares short:  4. 73 M 11. 15 M 11. 94 M
shares short prior month:  3. 54 M 9. 31 M 11. 96 M
short ratio:  3. 81   5. 72   3. 43  
short % of float:  7. 93 % 6. 40 % 2. 65 %

book value:  0. 67   13. 02   27. 49  
price/book:  4. 68   4. 21   8. 80  
gross profits:  23. 75 M 7. 67 B 36. 29 B
operating margins:  0. 00 % -380. 20 % -38. 44 %
EBITDA margins:  -34. 06 % 13. 59 % 23. 24 %
profit margins:  -27. 26 % 10. 94 % 14. 00 %
gross margins:  100. 00 % 36. 11 % 55. 16 %

1-yr max volatility:  246. 58 % --- ---
1-yr mean volatility:  4. 07 % 1. 50 % 1. 08 %

1-yr EPS:  -0. 72   2. 12   4. 26  
forward EPS:  -0. 41   3. 47   7. 14  
P/E:  -4. 37   2. 15   33. 17  
forward P/E:  -7. 27   -4. 03   17. 60  
PE/G:  -0. 00   0. 54   0. 34  
growth:  2034. 00 % 263. 03 % 78. 34 %
earnings high:  -0. 08   0. 91   1. 70  
earnings avg:  -0. 14   0. 71   1. 58  
earnings low:  -0. 21   0. 48   1. 46  
revenue high:  7. 19 M 2. 64 B 11. 26 B
revenue avg:  4. 06 M 2. 58 B 11. 09 B
revenue low:  -0. 00   2. 54 B 10. 90 B
return on assets:  -8. 62 % -2. 31 % 5. 31 %
return on equity:  -19. 44 % -82. 48 % 135. 30 %
revenue growth:  2034. 00 % 262. 60 % 72. 94 %

beta (1yr vs S&P500):  1. 39   1. 26   0. 91  
sharpe (1yr):  0. 79   0. 07   0. 77  

held % insiders:  8. 15 % 6. 08 % 3. 31 %
held % institutions:  41. 90 % 78. 36 % 69. 61 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-14 : AFMD
.    101.438 =       101.438 :: --> INITIAL WEIGHT <--
.    - 0.717 =       100.721 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 2.066 =        208.12 :: P/E factor
.    x 2.209 =       459.728 :: PE/G factor
.     x 1.53 =       703.282 :: beta factor
.    x 0.924 =       649.733 :: sharpe factor
.    x 2.541 =      1650.983 :: current ratio factor
.    x 1.211 =      1999.864 :: quick ratio factor
.    x 1.124 =      2247.039 :: short ratio factor
.    x 4.086 =      9180.997 :: revenue growth factor
.    x 1.058 =      9711.739 :: price-to-book factor
.    x 1.091 =     10599.226 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.114 =     22406.599 :: sector+industry 1-year gains factor
.    x 1.033 =     23154.936 :: industry 12-weeks return factor
.    x 1.305 =     30223.528 :: industry 2-weeks return factor
.    x 0.995 =     30077.103 :: "drift" penalty 4 days ago
.    x 0.995 =     29920.024 :: "drift" penalty 5 days ago
.    / 2.066 =     14480.178 :: overall "drift" factor
.    x 0.719 =     10417.723 :: largest single-day jump factor
.    x 0.071 =       741.475 :: low price factor
.    x 1.364 =      1011.132 :: notable returns + performance factor
.    x 1.786 =       1805.38 :: performance vs s&p500 factor
.                               --> PROJECTIONS <--
.     x 0.41 =       740.206 :: forward EPS factor
.    x 0.786 =        581.51 :: forward P/E factor
.    x 1.182 =       687.606 :: industry recommendation factor
.    x 2.835 =      1949.388 :: company recommendation factor
.    x 1.008 =      1964.298 :: factor historical industry gain for week 28
.    x 1.208 =      2373.208 :: target low factor
.    x 1.323 =      3138.587 :: target mean factor
.    x 1.048 =      3289.824 :: target high factor
.   x 10.996 =     36175.678 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =        13.791 :: reduced for readability
.    + 6.142 =        19.933 :: add/subtract for investor sentiment
.                               --> FINAL WEIGHT <--
.                   -999.999 :: FINAL WEIGHT for NASDAQ:AFMD


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org